Recent events
Recent events tied to this brand in public sources.
Back to profile2 entries
2026
Viva Biotech Reports 2026 Interim Results
Viva Biotech Holdings (1873.HK) reported interim results for the six months ended June 30, 2026, with total revenue of RMB 1,006.5 million, up 21.0% year on year, gross profit of RMB 341.7 million, up 0.7%, and gross margin of 34.0%. Net profit was RMB 100.9 million and adjusted non-IFRS net profit was RMB 128.3 million, both down from the prior-year period, mainly due to lower investment income, unfavorable foreign exchange movements and higher R&D expenses from new business initiatives. CRO revenue was RMB 405.1 million and Langhua Pharmaceutical CDMO revenue was RMB 601.4 million, up about 47.0% year on year.
2026
Langhua Pharmaceutical Builds 400 Cubic Meters of New Capacity
As of June 30, 2026, Langhua Pharmaceutical had total available production capacity of 860 cubic meters and was building an additional 400 cubic meters of capacity to serve future commercialization of new modalities. Its Taizhou factory had completed the design of a GMP peptide solid-phase synthesis production line and was about to begin installation.